Introduction {#s1}
============

Red blood cell distribution width (RDW) has served as a traditional biomarker for erythrocyte volume variability and as an indicator of erythrocyte homeostasis ([@B1]). However, the clinical significance of RDW is often overlooked and has historically been restricted to a narrow differential diagnosis, centered on anemia. Recent studies have shown that RDW elevation is seen in many human diseases, including cardiovascular diseases ([@B2], [@B3]), thrombosis ([@B3], [@B4]), and stroke ([@B4], [@B5]).

Inflammation has a profound impact on stroke development ([@B6]), and RDW is known to be closely associated with inflammatory responses on the basis of previous studies ([@B1], [@B4], [@B7], [@B8]). The relationship between RDW and stroke has begun to emerge with a large amount of evidence suggesting that elevated RDW might predict the incidence of stroke ([@B4], [@B9], [@B10]). Moreover, poor outcome in stroke is also related to a high baseline RDW level ([@B11]--[@B13]). Nevertheless, the clinical significance of RDW in stroke has not been comprehensively investigated owing to variations in sample populations and methodologies among current studies. This meta-analysis aims to evaluate the clinical value of RDW in stroke.

Methods {#s2}
=======

Search Strategy
---------------

This meta-analysis was registered in PROSPERO (International Prospective Register of Systematic Reviews) with the number CRD42018105318 and was conducted based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines ([Supplementary Table 6](#SM1){ref-type="supplementary-material"}). PubMed Central (PMC) and EMBASE databases were searched to identify studies up to May 2019. Medical subject headings and Emtree headings were used with the following keywords: "red blood cell distribution width OR RDW" and "prognosis OR prognostic OR survival OR outcome" and "stroke OR brain ischemia OR brain infarction OR cerebral infarction OR intracerebral hemorrhage OR intracranial hemorrhage." The full search strategy is presented in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}.

Study Selection
---------------

Prospective or retrospective studies that evaluated baseline RDW level prior to any treatment in patients with a confirmed diagnosis of ischemic stroke (IS) or subarachnoid hemorrhage (SAH) were included. Studies were identified as eligible if they provided hazard ratio (HR), odds ratio (OR), or relative risk ratio (RR) with 95% confidence interval (CI) regarding the risk of stroke or clinical outcomes. Studies without RDW at baseline were excluded. Furthermore, studies were eliminated if they involved patients who had nutritional deficiencies (vitamin B12 or folic acid deficiency) or hematological diseases (primary or secondary anemia, lymphoma/leukemia, and sickle cell disease/trait) or received a blood transfusion within 2 weeks. Conference abstracts, review articles, case reports, letters, animal studies, or *in vitro* studies were not included in the analysis. If two or more studies had duplicate or overlapping data, the study with a larger sample size was used. Two reviewers (SY-S and C-H) independently performed the study selection and resolved any disagreements via discussion.

Data Extraction
---------------

Two authors (SY-S and C-H) extracted data from all included studies, which was secondarily assessed by another author (RJ-K). Data extracted included the name of the first author, year of publication, country, study characteristics (sample size, age, and gender), clinical characteristics (population status and comorbid status), sample time, statistical methods used to define the cutoff value for RDW, and statistical sources of OR/RR (univariate or multivariate). A female-to-male ratio (F/M ratio) was introduced to precisely assess the various gender distributions among the included cohorts, which ranged from 0 to 3.2. The F/M ratio in a female-dominant subset was more than 1.2, whereas that in male-dominant cohort was \<0.8. This reference interval was defined based on averaged population size in a subgroup analysis. OR/RR and 95% CI were extracted for risk of stroke/carotid atherosclerosis/thromboembolism, mortality (short or long term), and functional outcome. SPSS 19.0 was used to calculate RR and their 95% CI on the basis of data in studies if not explicitly stated in the manuscript and no response from the investigators was received after two requests. All disagreements were resolved by consensus.

Outcomes
--------

In studies evaluating RDW as a predictor of stroke, carotid atherosclerosis, or thromboembolism in certain cohorts, the incidences of these events were recorded. In studies assessing RDW as a prognostic factor in stroke, the modified Rankin scale (mRS) was used to measure the functional outcomes in clinical follow-up. Death was defined as mRS of 6, whereas an unfavorable outcome was identified as mRS of 3--5.

Statistical Analyses
--------------------

STATA version 14.0 (STATA, College Station, TX) was utilized in all analyses. Multivariate-adjusted OR/RR was prioritized, and univariate OR/RR was included in the meta-analysis if no multivariate-adjusted OR/RR was reported. Pooled estimates with 95% CI were derived under the Mantel--Haenszel method. Given the large sample size, OR was assumed to be a good approximation to RR, and therefore, OR and RR were pooled together and simplified to the description OR/RR. Heterogeneity was explored comprehensively through the subgroup analysis and sensitivity analyses and was assessed using the χ^2^ test and expressed as the *I*^2^ index (25% = low, 50% = medium, and 75% = high) ([@B14]). The random-effects model was performed if heterogeneity was more than 50%. Assessment of publication bias was done by visual inspection of funnel plots, combined with Begg\'s test and Egger\'s test ([@B15], [@B16]). Moreover, Duval and Tweede\'s trim-and-fill method was applied to estimate the corrected effect size after adjustment for publication bias ([@B17]). Evaluation of the risk of bias in eligible studies was under predefined criteria ([@B18]--[@B20]). *P*-values \< 0.05 were considered statistically significant.

Results {#s3}
=======

Study Characteristics
---------------------

We identified 150 potentially relevant records and then screened them by titles and abstracts. Seventy-four studies did not meet inclusion criteria. The remaining 76 articles were retrieved for a close analysis. Ultimately, 31 studies with 3,487,896 patients were included in the analysis according to the inclusion and exclusion criteria ([Figure 1](#F1){ref-type="fig"}). The characteristics of the included studies can be seen in [Table 1](#T1){ref-type="table"} ([@B4], [@B5], [@B9]--[@B11], [@B13], [@B21]--[@B27], [@B29]--[@B44]).

![Flow diagram of the study selection process.](fneur-10-01237-g0001){#F1}

###### 

Main characteristics of 31 eligible studies included in the meta-analysis.

  **References**                   **Country**   **Patients number**   **Age[^\*^](#TN1){ref-type="table-fn"}**   **Gender (F/M)**   **Population status**                              **SAD**                                          **HTN**   **DM**   **Current smoking**   **Hyperlipidemia**   **Sample time[^\#^](#TN2){ref-type="table-fn"}**   **Cutoff definition**               **Cutoff value**   **Absolute % of high RDW**   **Statistical source**
  -------------------------------- ------------- --------------------- ------------------------------------------ ------------------ -------------------------------------------------- ------------------------------------------------ --------- -------- --------------------- -------------------- -------------------------------------------------- ----------------------------------- ------------------ ---------------------------- ------------------------
  Tonelli et al. ([@B4])           Canada        4,159                 NR                                         565/3,546          Coronary disease                                   NR                                               42.59%    14.06%   16.10%                NR                   NR                                                 4th quartile; continuous variable   13.80%             23.25%                       MV
  Ani et al. ([@B21])              USA           480                   NR                                         252/228            IS                                                 NR                                               63.40%    25.40%   22.40%                73.80%               NR                                                 4th quartile; continuous variable   13.90%             23.80%                       MV
  Chen et al. ([@B9])              China         3,226                 Mean 54.7                                  1,692/1,534        Community cohort                                   NR                                               28.90%    12.53%   36.05%                NR                   Within 24 h                                        4th quartile; continuous variable   13.10%             48.67%                       UV
  Kim et al. ([@B22])              Korea         847                   65.88 ± 12.45                              340/507            IS                                                 CAD, 16.8%                                       72.40%    29.40%   24.80%                21.10%               On admission                                       Continuous variable                 Non                Non                          MV
  Malandrino et al. ([@B23])       USA           2,497                 NR                                         1,387/1,110        DM                                                 VD, 58.7%; MI, 10.9%                             77.50%    100%     20.73%                NR                   NR                                                 4th quartile                        13.45%             48.46%                       MV
  Providência et al. ([@B24])      Portugal      247                   68.0 ± 10.5                                90/157             Non-valvular AF                                    TIA/stroke, 15.4%;VD, 52.2%;                     83.80%    22.70%   NR                    NR                   NR                                                 ROC                                 15%                48.80%                       UV
  Chugh et al. ([@B13])            USA           40                    52.8 ± 10.2                                30/10              SAH                                                CAD, 12.5%                                       63%       10%      67.50%                NR                   Within 24 h                                        ROC                                 NR                 30.00%                       MV
  Furer et al. ([@B25])            Israel        522                   66 ± 11                                    141/381            Community cohort                                   PVD, 22%; IHD, 42%; MI, 21%; stroke, 9%          72%       36%      43%                   80%                  NR                                                 NR                                  14.10%             30.86%                       UV
  Lee et al. ([@B26])              Korea         567                   52--74                                     217/350            Paroxysmal AF                                      MI, 2.6%; PAD, 0.3%; TIA/stroke, 9.0%            40.70%    13.40%   26.60%                5.80%                NR                                                 4th quartile; continuous variable   13.90%             27.37%                       MV
  Jia et al. ([@B27])              China         392                   64.8 ± 9.8                                 191/201            IS                                                 CAD, 11.2%                                       45.40%    13.78%   12.20%                NR                   NR                                                 4th quartile                        NR                 NR                           MV
  Saliba et al. ([@B28])           Israel        41,140                74.5 ± 13.1                                21,226/19,914      AF                                                 TIA/stroke, 21%;VD, 53.7%                        78.20%    35.30%   NR                    NR                   Within the previous 1 year                         4th quartile; continuous variable   15.00%             24.74%                       MV
  Söderholm et al. ([@B29])        Sweden        26,879                45--73                                     16,561/10,318      Community cohort                                   NR                                               60.80%    2.90%    28.20%                NR                   NR                                                 4th quartile                        NR                 25.14%                       MV
  Vayá et al. ([@B30])             Spain         163                   43.5 ± 11.4                                82/81              IS (cryptogenic subtype) vs. control               NR                                               NR        NR       NR                    NR                   NR                                                 NR                                  14%                15.19%                       MV
  Wang et al. ([@B31])             China         209                   78 ± 8                                     119/90             IS                                                 NR                                               77.47%    20.40%   NR                    NR                   Within 24 h                                        4th quartile                        13.20%             38.28%                       MV
  Lappegård et al. ([@B10])        Norway        1,152                 64.0 ± 12.7                                521/631            Community cohort                                   NR                                               73.50%    5.40%    35.50%                NR                   NR                                                 4th quartile                        13.50%             17.18%                       MV
  Miller et al. ([@B32])           USA           188                   53.0 ± 13.8                                42/146             Post-left ventricular assist devices vs. control   NR                                               NR        44.70%   NR                    NR                   Within 24 h                                        NR                                  18.10%             34.04%                       MV
  Akboga et al. ([@B33])           Turkey        277                   NR                                         178/99             IS (CVST subtype) vs. control                      NR                                               NR        NR       NR                    NR                   Within 24 h                                        NR                                  NR                 NR                           UV
  Al-Kindi et al. ([@B34])         USA           3,061                 61 ± 14                                    1,523/1,538        DM                                                 MI, 12.25%; stroke, 10.23%                       NR        100%     51.09%                NR                   NR                                                 4th quartile                        13.70%             24.47%                       MV
  Duchnowski et al. ([@B35])       Poland        500                   62.6 ± 12.4                                210/290            Post-cardiac valve surgery                         CAD, 35.6%; PAD, 7.6%; MI, 10.6%; stroke, 6.8%   65.80%    100%     24.20%                NR                   Within 24 h                                        ROC                                 14.10%             NR                           MV
  Huang et al. ([@B44])            USA           274                   59 ± 16                                    164/110            SAH                                                NR                                               47.06%    11.76%   NR                    NR                   NR                                                 Continuous variable                 Non                Non                          MV
  Fan et al. ([@B11])              China         362                   Median 63                                  146/216            IS                                                 CAD, 12.98%                                      80.66%    13.81%   NR                    17.40%               On admission                                       NR                                  NR                 NR                           UV
  Siegler et al. ([@B36])          USA           179                   54 (46--65)                                136/43             SAH                                                CAD, 7.82%; stroke, 4.47%; DVT, 1.68%            56.42%    6.09%    41.34%                NR                   NR                                                 Upper limit                         14.50%             52.99%                       MV
  Turcato et al. ([@B37])          Italy         316                   NR                                         162/154            IS post-thrombolysis                               MI, 12.03%                                       72.15%    16.77%   16.77%                33.54%               On admission                                       ROC; continuous variable            14.50%             21.84%                       UV
  Turcato et al. ([@B38])          Italy         837                   77 (68--83)                                NR                 IS                                                 NR                                               NR        NR       NR                    NR                   On admission                                       NR                                  13.00%             NR                           MV
  Liang et al. ([@B39])            China         108                   58 ± 11                                    24/84              IS                                                 MI, 10.19%; stroke, 23.15%                       46.30%    18.52%   50%                   NR                   Within 24 h                                        ROC                                 12.20%             44.00%                       MV
  Lee et al. ([@B40])              Korea         657                   69.4 ± 9.8                                 229/428            AF                                                 NR                                               48.60%    19.50%   24.00%                NR                   Within the previous 3 months                       ROC                                 13.60%             53.58%                       MV
  Mo et al. ([@B41])               China         442                   60.4 ± 14.3                                207/235            Hemodialysis                                       IHD, 14.6%                                       42.50%    31.40%   20.00%                NR                   Within the previous 6 months                       4th quartile                        17%                29.19%                       MV
  Pilling et al. ([@B42])          USA           240,477               55.05 ± 8.1                                115,811/124,666    Community cohort                                   NR                                               NR        NR       11.36%                NR                   NR                                                 4th quartile                        15%                2.75%                        MV
  Pinho et al. ([@B12])            Portugal      602                   60.5--82                                   345/257            IS post-thrombolysis                               CAD, 7.8%                                        68.40%    20.80%   NR                    43.90%               On admission                                       4th quartile; continuous variable   Non                Non                          MV
  Khongkhatithum et al. ([@B43])   Thailand      233                   NR                                         97/136             IS vs. control                                     NR                                               NR        NR       NR                    NR                   NR                                                 NR                                  15%                NR                           UV
  Tonelli et al. ([@B5])           USA           3,156,863             NR                                         NR                 Community cohort                                   NR                                               NR        NR       NR                    NR                   NR                                                 Upper limit                         15.60%             4.19%                        MV

*IS, acute ischemic stroke; SAH, subarachnoid hemorrhage; CVST, cerebral venous sinus thrombosis; SAD, symptomatic atherosclerotic disease; VD, vascular disease; PVD, peripheral vascular disease; IHD, ischemic heart disease; CAD, coronary artery disease; PAD, peripheral artery disease; MI, myocardial infarction; AF, atrial fibrillation; TIA, transient ischemia attack; DVT, deep venous thrombosis; HTN, hypertension; DM, diabetes mellitus; MV, multivariable model; UV, univariate model; RDW, red blood cell distribution width; NR, not reported*.

*Age reported as either mean ± standard deviation or median (range), if not otherwise specified*.

*Sample time was defined as time from stroke onset to time blood sample was taken*.

Twenty studies evaluated RDW as a risk factor of stroke occurrence in different cohorts, such as community cohort (*n* = 6), atrial fibrillation (AF) (*n* = 4), and diabetes mellitus (DM) (*n* = 2). In addition, 12 studies assessed the prognostic value of RDW in stroke, including IS (*n* = 9) and SAH (*n* = 3). A large number of studies reported comorbidities within their respective cohorts. Most frequently evaluated comorbidities included DM (*n* = 25), hypertension (HTN) (*n* = 23), current smoking (*n* = 19), and systemic atherosclerosis (*n* = 16). Hyperlipidemia was only described in seven studies.

Among studies evaluating stroke prognosis, a blood sample was drawn at admission or within 24 h prior to treatment. In studies exploring RDW as a potential risk factor for stroke, only a few studies (15%) reported sample collection time, in which baseline RDW values were obtained within 1 year before enrollment. Four different methods for defining cutoff values of RDW were observed in the included studies. Quartiles of RDW distribution were used most frequently (*n* = 14), followed by continuous variables (*n* = 9), area under the receiver-operating curve (ROC) analysis (*n* = 6), and upper limit of normal RDW range (*n* = 2). The range of cutoffs of RDW was 13.8--18.1%, likely due to variable definitive methods and demographic characteristics among the cohorts, such as age, gender, and country of origin.

The majority of studies enrolled patients younger than 65 years (*n* = 14), with a balanced gender composition (*n* = 10). The number of cohorts originally from Western countries (*n* = 21) was substantially more than that of cohorts from Eastern countries (*n* = 10). More than 70% of the included studies provided results analyzed from the multivariate regression model (*n* = 24) ([Supplementary Table 5](#SM1){ref-type="supplementary-material"}). In terms of study quality, 26 studies had quality scores \>7 ([Supplementary Table 2](#SM1){ref-type="supplementary-material"}).

Association Between Red Blood Cell Distribution Width and the Risk of Stroke/Carotid Atherosclerosis
----------------------------------------------------------------------------------------------------

A total of 20 studies with 3,535,653 patients provided OR/RR and 95% CI regarding the risk of IS/carotid atherosclerosis. Increased RDW was related to higher risk of combined stroke/carotid atherosclerosis (OR/RR = 1.544; 95% CI = 1.394--1.710; *I*^2^ = 64.6%; *P*~H~ \< 0.001; [Figure 2](#F2){ref-type="fig"}). By analyzing these pathologies independently, elevated RDW was found to be a risk factor in IS (OR/RR = 1.528; 95% CI = 1.372--1.703; *I*^2^ = 61.6%; *P*~H~ \< 0.001; [Figure 2](#F2){ref-type="fig"}) and carotid atherosclerosis (OR/RR = 1.869; 95% CI = 0.934--3.739; *I*^2^ = 86.7%; *P* \< 0.001; [Figure 2](#F2){ref-type="fig"}). RDW was not found to be a significant risk factor in SAH (OR/RR = 1.835; 95% CI = 0.888--3.792; *I*^2^ = 40.3%; *P*~H~ = 0.196; [Figure 2](#F2){ref-type="fig"}).

![Meta-analysis of the association between RDW and risk of stroke in patients. Results are presented as individual and pooled risk ratios (RRs) with 95% confidence intervals (CIs). RDW, red blood cell distribution width.](fneur-10-01237-g0002){#F2}

Given the association between higher RDW and IS incidence, a further subgroup analysis was used to stratify patients by population status, demographic factors (age, gender distribution, and country), vascular risk factors (HTN, DM, and current smoking), and methodological factors (cutoff value, definition of cutoff value, and OR/RR calculation) ([Table 2](#T2){ref-type="table"}). Elevated RDW conferred increased risk in not only populations with conventionally higher risk of stroke, such as AF (OR/RR = 1.292; 95% CI = 1.107--1.508) and DM (OR/RR = 2.101; 95% CI = 1.488--2.968), but also non-selected community residents (OR/RR = 1.245; 95% CI = 1.216--1.275). No significant effect of high RDW was identified in either the elderly or younger populations. In terms of gender distribution, male-dominant cohorts with elevated RDW (OR/RR = 1.853; 95% CI = 1.505--2.283) were more prone to develop IS than were female-dominant cohorts (OR/RR = 1.330; 95% CI = 1.051--1.683). These results remained significant in studies performed in both Eastern and Western countries. Furthermore, the predictive value of RDW was found to be independent of vascular risk factors, such as HTN, DM, and current smoking status. Cutoff values of RDW varied among studies. Studies with cutoff values of RDW \<15% were associated with worse OR/RR (OR/RR = 1.641; 95% CI = 1.453--1.855). The fourth quartile of RDW value became the most commonly used method to define a cutoff value, whereas a ROC analysis had the highest pooled OR/RR and the lowest heterogeneity among other subgroups (OR/RR = 1.890; 95% CI = 1.357--2.632, *I*^2^ = 30.0%). Both the multivariate and univariate models observed the adverse effect of RDW on IS.

###### 

Subgroup analyses of the associations between RDW and risk of ischemic stroke.

  **Stratified analyses**                              **No. of patients**   **No. of studies**   **Model**   **Pooled HR (95% CI)**                                   ***P*-value**   ***P*~**D**~ value**   **Heterogeneity**   
  ---------------------------------------------------- --------------------- -------------------- ----------- -------------------------------------------------------- --------------- ---------------------- ------------------- ---------
  **Population status**                                                                                                                                                                \<0.001                                    
  Community cohort                                     3,453,437             5                    Fixed       1.245 (1.216, 1.275)                                     \<0.001                                2.9%                0.390
  Atrial fibrillation                                  41,954                3                    Random      1.292 (1.107, 1.508)                                     0.001                                  71.7%               0.007
  Case (stroke)--control study                         673                   3                    Random      2.047 (1.120, 3.740) [^\*^](#TN3){ref-type="table-fn"}   0.020                                  65.8%               0.020
  Diabetes mellitus                                    5,558                 2                    Fixed       2.101 (1.488, 2.968)                                     \<0.001                                \<0.001             0.381
  **Demographic factors**                                                                                                                                                                                                         
  **Age**                                                                                                                                                                              \<0.001                                    
  \<65                                                 248,146               7                    Random      1.621 (1.282, 2.050)                                     \<0.001                                65.3%               0.008
  ≥65                                                  69,490                5                    Fixed       1.393 (1.232, 1.575)                                     \<0.001                                31.5%               0.211
  **Gender distribution**                                                                                                                                                              \<0.001                                    
  Female dominant                                      29,653                3                    Random      1.330 (1.051, 1.683)                                     0.017                                  67.9%               0.045
  Balanced                                             314,981               8                    Fixed       1.521 (1.360, 1.700)                                     \<0.001                                20.0%               0.271
  Male dominant                                        6,829                 8                    Fixed       1.853 (1.505, 2.283)                                     \<0.001                                19.5%               0.275
  **Country**                                                                                                                                                                          \<0.001                                    
  Eastern                                              5,125                 7                    Fixed       1.682 (1.344, 2.104)                                     \<0.001                                31.0%               0.191
  Western                                              3,502,735             14                   Random      1.468 (1.315, 1.639)                                     \<0.001                                65.0%               0.001
  **Vascular risk factors**                                                                                                                                                                                                       
  **Presence of hypertension**                                                                                                                                                         \<0.001                                    
  \<60%                                                35,043                6                    Fixed       1.546 (1.326, 1.803)                                     \<0.001                                45.1%               0.105
  ≥60%                                                 71,743                6                    Fixed       1.451 (1.292, 1.630)                                     \<0.001                                39.7%               0.141
  **Presence of diabetes mellitus**                                                                                                                                                    \<0.001                                    
  \<20%                                                61,980                7                    Fixed       1.446 (1.292, 1.618)                                     \<0.001                                24.4%               0.243
  ≥20%                                                 47,867                6                    Random      1.880 (1.434, 2.465)                                     \<0.001                                50.5%               0.073
  **Presence of current smoking**                                                                                                                                                      \<0.001                                    
  \<25%                                                249,212               7                    Fixed       1.851 (1.547, 2.215)                                     \<0.001                                16.8%               0.302
  ≥25%                                                 59,725                5                    Fixed       1.417 (1.262, 1.591)                                     \<0.001                                0.0%                0.555
  **Methodological factors**                                                                                                                                                                                                      
  **Cutoff value**                                                                                                                                                                     \<0.001                                    
  \<15%                                                41,302                10                   Fixed       1.641 (1.453, 1.855)                                     \<0.001                                22.8%               0.233
  ≥15%                                                 3,439,868             8                    Random      1.572 (1.260, 1.962)                                     \<0.001                                59.8%               0.015
  **Definition of cutoff value**                                                                                                                                                       \<0.001                                    
  4th quartile                                         348,920               11                   Fixed       1.485 (1.357, 1.625)                                     \<0.001                                32.1%               0.143
  Continuous variable                                  49,092                4                    Fixed       1.110 (1.069, 1.153)                                     \<0.001                                46.8%               0.131
  ROC curve analysis                                   1,404                 3                    Fixed       1.890 (1.357, 2.632)                                     \<0.001                                30.0%               0.240
  **HR calculation**[^‡^](#TN4){ref-type="table-fn"}                                                                                                                                   \<0.001                                    
  Multivariate                                         3,503,397             13                   Random      1.560 (1.365, 1.784)                                     \<0.001                                65.7%               \<0.001
  Univariate                                           4,463                 7                    Random      1.651 (1.218, 2.237)                                     0.001                                  58.4%               0.025

*RDW, red blood cell distribution width; HR, hazard ratio; CI, confidence interval*.

*The result should be described as pooled OR (95% CI). All the three case--control studies ([@B30], [@B33], [@B43]) provided "OR" as results*.

*HRs were extracted from multivariate Cox proportional hazards models, univariate Cox proportional hazards models or survival curve analysis*.

After a sensitivity analysis under the "one study removed" model, the pooled OR/RR was significantly affected by the exclusion of Tonelli et al. ([Supplementary Table 3](#SM1){ref-type="supplementary-material"}). Heterogeneity reduced by 5%, and the result remained statistically significant (OR/RR = 1.641; 95% CI = 1.448--1.859).

Association Between Red Blood Cell Distribution Width and Mortality in Stroke
-----------------------------------------------------------------------------

Ten studies with 4,782 patients were analyzed for mortality. Overall, elevated RDW was associated with increased mortality (OR/RR = 1.278; 95% CI = 1.221--1.337; *I*^2^ = 49.3%; *P*~H~ = 0.019; [Figure 3](#F3){ref-type="fig"}). This adverse effect of higher RDW level was stronger in IS (OR/RR = 1.317; 95% CI = 1.212--1.432) than in hemorrhagic stroke (OR/RR = 1.266; 95% CI = 1.103--1.453; [Table 3](#T3){ref-type="table"}).

![Meta-analysis of the association between RDW and mortality in patients. Results are presented as individual and pooled risk ratios (RRs) with 95% confidence intervals (CIs). RDW, red blood cell distribution width.](fneur-10-01237-g0003){#F3}

###### 

Subgroup analyses of the associations between RDW and mortality in stroke.

  **Stratified analyses**                                   **No. of patients**   **No. of studies**   **Model**   **Pooled HR (95% CI)**   ***P*-value**   ***P*~**D**~ value**   **Heterogeneity**   
  --------------------------------------------------------- --------------------- -------------------- ----------- ------------------------ --------------- ---------------------- ------------------- -------
  **Stroke subtype**                                                                                                                                        \<0.001                                    
  Ischemic stroke                                           4,468                 8                    Random      1.317 (1.212, 1.432)     \<0.001                                54.9%               0.014
  Subarachnoid hemorrhage                                   314                   2                    Fixed       1.266 (1.103, 1.453)     0.018                                  42.3%               0.177
  **Assessment time**                                                                                                                                                                                  
  **Short-term mortality**                                                                                                                                  \<0.001                                    
  In-hospital mortality                                     845                   3                    Random      1.528 (1.035, 2.257)     \<0.001                                74.0%               0.021
  3-month mortality                                         887                   2                    Fixed       1.424 (1.196, 1.697)     \<0.001                                49.7%               0.158
  **Long-term mortality**                                                                                                                                                                              
  1-year mortality                                          3,191                 5                    Fixed       1.267 (1.175, 1.367)     \<0.001                                48.5%               0.100
  Long-term mortality[^\*^](#TN5){ref-type="table-fn"}      1,994                 3                    Fixed       1.226 (1.145, 1.313)     \<0.001                                21.9%               0.278
  **Demographic factors**                                                                                                                                                                              
  **Age**                                                                                                                                                   \<0.001                                    
  \<65                                                      2,930                 6                    Fixed       1.238 (1.169, 1.310)     \<0.001                                9.5%                0.356
  ≥65                                                       1,852                 4                    Random      1.440 (1.204, 1.721)     \<0.001                                70.4%               0.009
  **Gender distribution**                                                                                                                                   \<0.001                                    
  Female dominant                                           1,125                 4                    Random      1.353 (1.089, 1.682)     0.006                                  66.0%               0.019
  Balanced                                                  1,948                 3                    Random      1.388 (1.088, 1.770)     \<0.001                                50.7%               0.108
  Male dominant                                             1,709                 3                    Fixed       1.273 (1.200, 1.351)     \<0.001                                43.9%               0.129
  **Country**                                                                                                                                               \<0.001                                    
  Eastern                                                   1,418                 3                    Random      1.311 (1.150, 1.495)     \<0.001                                69.2%               0.011
  Western                                                   3,364                 7                    Fixed       1.296 (1.213, 1.385)     \<0.001                                35.0%               0.138
  **Vascular risk factors**                                                                                                                                                                            
  **Presence of hypertension**                                                                                                                              \<0.001                                    
  \<60%                                                     274                   1                    --          --                       --                                     --                  --
  ≥60% and 70%                                              1,622                 4                    Fixed       1.302 (1.203, 1.409)     \<0.001                                39.2%               0.176
  ≥70%                                                      2,886                 5                    Random      1.338 (1.175, 1.522)     \<0.001                                64.1%               0.007
  **Presence of diabetes mellitus**                                                                                                                         \<0.001                                    
  \<20%                                                     2,644                 6                    Fixed       1.314 (1.177, 1.466)     \<0.001                                47.4%               0.055
  ≥20%                                                      2,138                 4                    Random      1.307 (1.225, 1.394)     \<0.001                                58.0%               0.049
  **Presence of hyperlipidemia**                                                                                                                            \<0.001                                    
  \<25%                                                     1,209                 2                    Fixed       1.257 (1.182, 1.337)     \<0.001                                39.3%               0.176
  ≥25%                                                      1,398                 3                    Random      1.339 (1.100, 1.630)     0.004                                  70.6%               0.033
  **Presence of current smoking**                                                                                                                           \<0.001                                    
  \<25%                                                     2,143                 4                    Fixed       1.358 (1.266, 1.458)     \<0.001                                40.4%               0.152
  ≥25%                                                      1,192                 2                    Fixed       1.333 (1.031, 1.724)     0.029                                  25.6%               0.261
  **Methodological factors**                                                                                                                                                                           
  **Sample time**[^&^](#TN6){ref-type="table-fn"}                                                                                                           \<0.001                                    
  on admission                                              2,127                 3                    Random      1.289 (1.174,1.415)      \<0.001                                56.4%               0.043
  Within 24 h                                               749                   3                    Random      3.492 (1.301, 9.372)     0.013                                  71.8%               0.014
  **Cutoff value**                                                                                                                                          --                                         
  \<15%                                                     3,259                 6                    Random      1.908 (1.403, 2.594)     \<0.001                                65.7%               0.403
  ≥15%                                                      274                   1                    --          --                       --                                     --                  --
  **Definition of cutoff value**                                                                                                                            \<0.001                                    
  4th quartile                                              2,443                 4                    Random      1.856 (1.207, 2.853)     0.005                                  71.3%               0.007
  Continuous variable                                       1,929                 3                    Fixed       1.302 (1.221, 1.389)     \<0.001                                0.0%                0.637
  ROC curve analysis                                        856                   3                    Random      2.207 (1.179, 4.130)     0.013                                  62.9%               0.067
  **ORs/RRs calculation**[^‡^](#TN7){ref-type="table-fn"}                                                                                                   \<0.001                                    
  Multivariate                                              4,466                 9                    Fixed       1.270 (1.211, 1.331)     \<0.001                                43.1%               0.056
  Univariate                                                1,178                 3                    Random      2.441 (0.974, 6.118)     0.057                                  76.3%               0.015

*RDW, red blood cell distribution width; HR, hazard ratio; CI, confidence interval; ROC, receiver-operating curve; ORs, odds ratios; RRs, risk ratios*.

*Long-term mortality was defined as hazard of death due to all causes or stroke more than 1 year by the end of follow-up*.

*Sample time was defined as time from stroke onset to time blood sample was taken*.

*HRs were extracted from multivariate Cox proportional hazards models, univariate Cox proportional hazards models, or survival curve analysis*.

The subgroup analysis of RDW effect on mortality was performed regarding the aforementioned variables ([Table 3](#T3){ref-type="table"}). Higher RDW was more strongly correlated with short-term mortality (in-hospital mortality and 3-month mortality) than relatively long-term mortality (1-year mortality). The prognostic value of RDW was independent of all demographic factors. Cohorts with patients older than 65 years or from Eastern countries had higher pooled mortality OR/RR. In addition, increased mortality was observed in populations with a high presence of HTN (\>70%) or hyperlipidemia (\>25%). When stratified by methodological factors, combined OR/RR remained significant.

In the sensitivity analysis under "one study removed" model, estimated OR/RR was not significantly affected by the exclusion of any study ([Supplementary Figure 3](#SM1){ref-type="supplementary-material"}).

Association Between Red Blood Cell Distribution Width and Functional Outcome in Ischemic Stroke
-----------------------------------------------------------------------------------------------

Seven studies with 2,929 patients evaluated the relationship between RDW and functional outcome in stroke. In a pooled analysis, no significant impact on functional outcome was identified (OR/RR 1.255; 95% CI = 1.159--1.360; *I*^2^ = 0.0%; *P*~H~ = 0.537; [Figure 4](#F4){ref-type="fig"}). Increased RDW was associated with unfavorable functional outcome both at discharge (OR/RR = 1.220; 95% CI = 1.070--1.39) and at 3-month follow-up (OR/RR = 1.277; 95% CI = 1.155--1.413). The subgroup analysis was not conducted owing to the low heterogeneity and sample size.

![Meta-analysis of the association between RDW and modified Rankin scale (mRS) functional outcome in patients. Results are presented as individual and pooled risk ratios (RRs) with 95% confidence intervals (CIs). RDW, red blood cell distribution width.](fneur-10-01237-g0004){#F4}

Publication Bias
----------------

Evidence of publication bias in studies evaluating RDW as a risk factor ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}) and as a prognostic factor ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}) was observed for mortality in stroke by Egger\'s test. All combined OR/RR remained significant after the trim-and-fill method ([Supplementary Table 4](#SM1){ref-type="supplementary-material"}). Increased RDW was still associated with a higher risk of stroke and poor prognosis after stroke following adjustment for publication bias.

Discussion {#s4}
==========

RDW is a conventional parameter, which can be easily acquired with a complete blood count (CBC) test. However, its role in reflecting inflammation has only attracted attention recently ([@B1], [@B4], [@B7], [@B8]). Inflammation is known to be closely related to stroke occurrence and recurrence ([@B6], [@B45]), and the relationship between baseline RDW and stroke has been previously assessed in other studies, albeit with variable results. This meta-analysis provides a panoramic assessment of RDW as a risk factor for stroke in various cohorts and as a negative predictor of functional outcomes. Higher RDW was found to be associated with an increased risk of IS, not only in patients with AF or DM but also in community cohorts. Further, an unfavorable functional outcome and elevated short-term mortality after stroke was identified in patients with higher baseline RDW.

Despite robust results in this analysis that higher RDW correlates with an increased risk of IS and serves as a negative prognostic factor in stroke outcome, the underlying mechanism remains unclear. Given that patients with nutritional deficiency, hematological disease, and blood transfusion were excluded from the presented analysis, the majority of patients had RDW values within the normal range, albeit on the upper limit of normal. This may suggest accelerated red blood cell destruction or, more commonly, ineffective erythropoiesis ([@B46]). In either case, there is an increased number of immature red blood cells presented in peripheral blood, resulting in elevated RDW.

It has been well-documented that inflammation is associated with the process of IS, from initial ischemia to infarction and secondary repair ([@B6], [@B45]). During stroke-induced inflammation, various cytokines are released and affect erythropoiesis, erythropoietin (EPO) production ([@B47], [@B48]), inhibition of erythroid progenitors ([@B49]), and reduction in iron release ([@B50], [@B51]). Further, RDW has been previously found to have a positive association with plasma inflammatory biomarkers, such as C-reactive protein (CRP) ([@B7], [@B8]), erythrocyte sedimentation rate (ESR) ([@B52]), and interleukin (IL)-6 ([@B53], [@B54]). Higher RDW, even within the normal range, may worsen the inflammatory state in stroke, leading to worse outcomes following IS. Furthermore, inflammation is known to precipitate a thrombotic state, which may underlie the increased incidence of stroke in patients with elevated baseline RDW levels ([@B55], [@B56]). Taken all together, elevated RDW serves as a marker for increased inflammation, whether stroke induced, leading to poor outcomes after stroke, or marking a pro-thrombotic state, resulting in increased incidence of IS.

Recent studies have shown that RDW value is influenced by demographic factors ([@B57]), including age, gender, and race. A gradual increase in RDW with age has been reported in healthy controls ([@B1]), whereas the relationship between gender and RDW is still controversial. Some studies have suggested that females have a slightly higher RDW than have males ([@B58], [@B59]), whereas others indicate no significant gender-based difference in RDW values ([@B60], [@B61]). Studies evaluating the impact of race have found that the relationship between RDW and stroke is weaker in blacks than that in whites ([@B62]). The subgroup analysis in this study was used to stratify the results by demographic factors. The results revealed that elevated RDW could predict stroke occurrence and poor survival outcome, independent of age, gender, and race. However, the clinical significance of RDW was statistically more significant in populations from Eastern countries. RDW also showed a slightly different predictive value on risk and prognosis when stratified by age and gender. Cohorts of patients younger than 65 years had a higher risk of IS but had lower mortality than do the elderly subgroup. This result may be due to the fact that the majority of studies only assessed all-cause death, rather than stroke-related death. For this reason, future studies should evaluate short-term mortality or long-term stroke-related mortality as clinical outcomes. Concerning gender, increasing incidence of IS was observed in male-dominant subsets, whereas female-dominant cohorts with higher RDW were inversely associated with survival.

Baseline RDW was evaluated as both continuous and categorical (quartiles) variables. The fourth quartile was often used to define cutoff values, ranging from 13.8 to 18.1%. However, studies utilizing a ROC analysis to identify cutoffs had more negative pooled OR/RR and lower heterogeneity. Additionally, assessing RDW as a continuous variable was more likely to have lower combined OR/RR and narrower 95% confidence intervals. The cutoff value of 14.6% has conventionally been used for anemia in the past ([@B63]). This review found that most studies chose a cutoff under 15%, which was predictive of poorer clinical outcomes. These results remained significant after a sensitivity analysis. As such, future studies could empirically use 15% as a cutoff value, conduct an individual ROC analysis, or consider RDW as a continuous variable in patients with stroke.

Several limitations should be mentioned. First, RDW could be combined with other hematological parameters, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet distribution width (PDW), to systematically and globally reflect the inflammatory and thrombotic state. Second, there remains controversy regarding whether an original RDW value at a certain time point or a calculated RDW value within a certain period after stroke would better predict prognosis. A calculated RDW could include mean, median, maximum, or delta RDW to encompass the dynamic nature of the inflammatory state. Future studies should follow this dynamic change of RDW in the post-stroke window, similar to that seen in Siegler et al. ([@B36]), Chugh et al. ([@B13]), and Saliba et al. ([@B28]). Third, no study has evaluated the role of RDW in predicting stroke recurrence. Long-term follow-up is suggested to study the association between RDW and stroke recurrence. Finally, there was mild heterogeneity among the included studies owing to varying populations, sample times, and methodologies to define the cutoff value of RDW. However, heterogeneity by a subgroup analysis and a sensitivity analysis (under "one study removed" model) was explored. In the subgroup analysis, heterogeneity in most of the subgroups was reduced from high-to-medium level to medium-to-low level (including subgroups of age, cutoffs of RDW, and methodologies). In the sensitivity analysis, the pooled OR/RR was significantly affected by the exclusion of Tonelli et al. as detailed above ([Supplementary Table 3](#SM1){ref-type="supplementary-material"}). Heterogeneity reduced by 5%, but the result remained statistical significant (OR/RR = 1.641; 95% CI = 1.448--1.859). To further eliminate confounding, multivariate-adjusted OR/RR was preferentially selected, and univariate OR/RR was only included in the meta-analysis if no multivariate-adjusted OR/RR existed. The majority of the included studies utilized multivariate analysis (*n* = 24), meaning that individual studies had already adjusted for potential confounding factors (gender, age, and other inflammatory markers) prior to this meta-analysis.

Conclusions {#s5}
===========

Baseline RDW is a promising predictor of IS occurrence and outcome, independent of demographic and methodological factors. Notably, in the subgroup analysis, male-dominant cohorts with higher RDW tend to have a higher risk of stroke, and elevated RDW in the elderly population is strongly associated with mortality. Further investigation into the underlying etiology between this association between RDW and stroke risk and prognosis is certainly warranted.

Data Availability Statement {#s6}
===========================

The datasets generated for this study are available on request to the corresponding author.

Author Contributions {#s7}
====================

RM: manuscript drafting and revision and study concept and design. S-YS: manuscript drafting and revision, study concept and design, collection, assembly, and interpretation of the data. CH and RK: collection, assembly, and interpretation of the data. RM, S-YS, CH, RK, X-XZ, XD, and WH: manuscript writing and final approval of manuscript. DD and YD deeply edited the revised version and contributed critical revision.

Conflict of Interest
--------------------

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We would like to thank all authors who reported their relevant data on PMC and EMBASE.

**Funding.** This study was sponsored by the National Key R&D Program of China (2017YFC1308400), the National Natural Science Foundation (81371289), and the Project of Beijing Municipal Top Talent for Healthy Work of China (2014-2-015).

Supplementary Material {#s9}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2019.01237/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Yannick Béjot, Centre Hospitalier Regional Universitaire De Dijon, France

[^2]: Reviewed by: Linxin Li, University of Oxford, United Kingdom; Maurice Giroud, Centre Hospitalier Regional Universitaire De Dijon, France

[^3]: This article was submitted to Stroke, a section of the journal Frontiers in Neurology
